Clinical Trial Update: Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of ethyl icosapentate plus physical activity for fatigue in patients with advanced cancer was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatigue
• Malignant Neoplasm

Drugs mentioned

• Ethyl Icosapentate (ethyl icosapentate)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Malignant Neoplasm, Fatigue | Phase 2 | Status: TERMINATED | Results posted: 2021-06-10